Recent Publications by DOV Pharmaceutical: |
Designing new treatments for depression and anxiety.
Depression and anxiety are disabling disorders that affect many... | 13th June, 2008
| DOV Pharmaceutical
| IDrugs. 2008 Mar;11(3):189-97.
|
The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.
Selective inhibitors of biogenic amine (e.g., serotonin, norepinephrine,... | 25th March, 2008
| Department of Preclinical Pharmacology, DOV Pharmaceutical, Inc., 150
| J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.
DOI Direct Link |
AMPA receptors: a target for novel antidepressants?
Depression and anxiety are disabling disorders that affect many... | 1st March, 2008
| DOV Pharmaceutical, Inc., Somerset, New Jersey 08873, USA.
| Biol Psychiatry. 2008 Feb 15;63(4):347-8.
DOI Direct Link |
Pharmacokinetics, disposition, and metabolism of bicifadine in humans.
Bicifadine [DOV 220,075;... | 22nd February, 2008
| DOV Pharmaceutical, Inc., 150 Pierce St., Somerset, NJ 08873, USA.
| Drug Metab Dispos. 2008 Feb;36(2):252-9. Epub 2007 Nov 8.
DOI Direct Link |
Triple uptake inhibitors: therapeutic potential in depression and beyond.
Drugs that interfere with the uptake and/or metabolism of biogenic amines... | 15th September, 2007
| DOV Pharmaceutical, Inc.,
| Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77.
DOI Direct Link |
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.
Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) inhibits monoamine... | 31st July, 2007
| DOV Pharmaceutical, Inc., 150 Pierce St., Somerset, NJ 08873-4185, USA.
| J Pharmacol Exp Ther. 2007 Jun;321(3):1208-25. Epub 2007 Feb 26.
DOI Direct Link |
Triple reuptake inhibitors ("broad spectrum" antidepressants).
The majority of antidepressants in current use inhibit the uptake of... | 30th May, 2007
|
| CNS Neurol Disord Drug Targets. 2007 Apr;6(2):141-9.
|
Neuropsychological symptom dimensions in bipolar disorder and schizophrenia.
BACKGROUND: While neurocognitive (NC) impairments have been well... | 10th May, 2007
| DOV Pharmaceutical Inc., Hackensack, NJ, USA.
| Bipolar Disord. 2007 Feb-Mar;9(1-2):71-92.
DOI Direct Link |
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
DOV 216,303 [(+/-)-1-(3,4-dichlorophenyl)-3-azabicyclo-[3.1.0]hexane... | 29th September, 2006
| DOV Pharmaceutical, Inc,
| CNS Drug Rev. 2006 Summer;12(2):123-34.
DOI Direct Link |
Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.
Benzodiazepines remain widely used for the treatment of anxiety disorders... | 14th July, 2005
| DOV Pharmaceutical, Inc., 433 Hackensack Avenue, Hackensack, NJ 07601,
| Proc Natl Acad Sci U S A. 2005 May 17;102(20):7380-5. Epub 2005 May 3.
DOI Direct Link |
Anxioselective anxiolytics: can less be more?
Benzodiazepines remain widely used for the treatment of anxiety disorders... | 15th June, 2005
| DOV Pharmaceutical, Inc., 433 Hackensack Avenue, Hackensack, NJ 07601,
| Eur J Pharmacol. 2004 Oct 1;500(1-3):441-51.
DOI Direct Link |
DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
This report describes the first evaluation in humans of DOV 216,303, a... | 9th April, 2005
| DOV Pharmaceutical, Inc, Continental Plaza, 433 Hackensack Avenue,
| J Clin Pharmacol. 2004 Dec;44(12):1360-7.
DOI Direct Link |
Beyond monoamine-based therapies: clues to new approaches.
Advances in antidepressant therapy have resulted in agents with fewer... | 13th October, 2004
| DOV Pharmaceutical Inc., 433 Hackensack Ave., Hackensack, NJ 07601, USA.
| J Clin Psychiatry. 2002;63 Suppl 2:19-23.
|
"Broad spectrum" antidepressants: is more better for the treatment of depression?
The majority of antidepressants in current use selectively inhibit the... | 3rd December, 2003
| DOV Pharmaceutical, Inc., 433 Hackensack Avenue, Hackensack, NJ 07601,
| Life Sci. 2003 Nov 7;73(25):3175-9.
|
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
DOV 21,947 [(+)-1-(3,4-dichlorophenyl)-3-azabicyclo-[3.1.0]hexane... | 24th May, 2003
| DOV Pharmaceutical, Inc., Continental Plaza, 433 Hackensack Avenue,
| Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104.
|
